Monitoring Parkinson's Disease with MNCD Classification and Levodopa Treatment
Author Information
Author(s): Santos-García Diego, López-Manzanares Lydia, Muro Inés, Lorenzo-Barreto Pablo, Casas Peña Elena, García-Ramos Rocío, Fernández Valle Tamara, Morata-Martínez Carlos, Baviera-Muñoz Raquel, Martínez-Torres Irene, Álvarez-Sauco María, Alonso-Modino Déborah, Legarda Inés, Valero-García María Fuensanta, Suárez-Muñoz José Andrés, Martínez-Castrillo Juan Carlos, Perona Ana Belén, Salom Jose María, Cubo Esther, Valero-Merino Caridad, López-Ariztegui Nuria, Alonso Pilar Sánchez, Novo Ponte Sabela, Gamo Gónzalez Elisa, Martín García Raquel, Espinosa Raúl, Carmona Mar, Feliz Cici Esmerali, García Ruíz Pedro, Muñoz Ruíz Teresa, Fernández Rodríguez Beatriz, Alvarez-Santullano Marina Mata, Perez-Lloret Santiago
Primary Institution: Department of Neurology, Hospital Universitario de A Coruña
Hypothesis
Can the MNCD classification effectively monitor clinical stages and responses to treatment in advanced Parkinson's disease patients?
Conclusion
The MNCD classification is useful for classifying advanced Parkinson's disease patients and monitoring their response to device-aided therapy.
Supporting Evidence
- The MNCD classification showed a significant decrease in the percentage of patients in stage 4 from 17.9% to 9%.
- The MNCD total score decreased significantly from 6.27 to 5.21.
- Motor and non-motor symptom burdens decreased significantly after treatment.
- Independence for activities of daily living improved from 27 to 33 patients.
- Correlation was found between MNCD score improvement and clinical global impression of change.
Takeaway
This study shows that a new way to classify Parkinson's disease can help doctors see how well patients are doing after treatment.
Methodology
A multicenter observational retrospective study was conducted on patients starting levodopa-entacapone-carbidopa intestinal gel treatment, assessing changes in MNCD classification and scores.
Potential Biases
Potential biases in patient selection and treatment evaluation due to the observational nature of the study.
Limitations
The study's retrospective design and small sample size limit the generalizability of the findings.
Participant Demographics
67 patients, 58.2% males, average age 69.9 years, mean disease duration 14.4 years.
Statistical Information
P-Value
0.001
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website